Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Receivables: 2024-2025

Historic Change in Receivables for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Sep 2025 value amounting to $1.2 million.

  • Tonix Pharmaceuticals Holding's Change in Receivables fell 27.39% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year change of. This contributed to the annual value of $3.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Change in Receivables is $1.2 million, which was up 220.26% from -$992,000 recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Change in Receivables peaked at $1.6 million during Q3 2024, and registered a low of -$1.3 million during Q4 2024.
  • Over the past 2 years, Tonix Pharmaceuticals Holding's median Change in Receivables value was -$371,000 (recorded in 2025), while the average stood at $34,800.
  • Data for Tonix Pharmaceuticals Holding's Change in Receivables shows a maximum YoY decreased of 27.39% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Tonix Pharmaceuticals Holding's Change in Receivables stood at -$1.3 million in 2024, then decreased by 27.39% to $1.2 million in 2025.
  • Its Change in Receivables stands at $1.2 million for Q3 2025, versus -$992,000 for Q2 2025 and -$371,000 for Q1 2025.